Hyperphosphatemia Market Growth Fueled by New Therapies and Rising Chronic Kidney Disease Burden
The hyperphosphatemia market is projected for steady growth from 2026 to 2036, driven by the increasing prevalence of chronic kidney disease and advancements in novel therapeutics.
The market for hyperphosphatemia is expected to experience steady growth during the forecast period of 2026-2036. This expansion is primarily fueled by the rising global prevalence of chronic kidney disease (CKD), diabetes, and hypertension, coupled with an increasing population of dialysis patients.
The condition, characterized by elevated phosphate levels in the blood, is often associated with chronic kidney failure. Market analyses conducted in the United States, Europe, and Japan indicate a continuous rise in the number of patients with elevated phosphate levels, making them susceptible to hyperphosphatemia. This growth reflects a broader health trend towards improved diagnosis and management of chronic conditions.
The emergence of novel therapies, such as TS-172 developed by Taisho, is also anticipated to contribute to market development. These new treatments offer potentially more effective and targeted solutions for patients suffering from hyperphosphatemia.
The growing number of patients undergoing dialysis is a significant factor driving market expansion. The need for dialysis treatment directly correlates with the progression of chronic kidney disease, increasing the incidence of hyperphosphatemia and, consequently, the demand for its management.